rilonacept

Home
Ligands
rilonacept

GtoPdb Ligand ID: 6790

Synonyms: Arcalyst® | IL-1 Trap | interleukin-1 Trap

rilonacept is an approved drug (FDA (2008), EMA (2009))

Compound class: Peptide or derivative

Comment: Rilonacept is a fusion protein consisting of the binding domains of the IL-1 receptor (IL-1R) and the IL-1 receptor accessory protein (IL-1RAcP) linked to the Fc portion of human IgG1.

No information available.

No information available.

Summary of Clinical Use
Currently used in the treatment of cryopyrin-associated periodic syndrome (CAPS). Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells syndrome; and CINCA syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 protein mutations. EMA approval has been withdrawn.

Summary of Clinical Use

Currently used in the treatment of cryopyrin-associated periodic syndrome (CAPS). Cryopyrin-associated periodic syndrome includes three previously distinct disorders: Familial cold autoinflammatory syndrome; Muckle-Wells syndrome; and CINCA syndrome, that are now considered to represent a disease continuum, all caused by NLRP3 protein mutations.

EMA approval has been withdrawn.

Mechanism Of Action and Pharmacodynamic Effects
Rilonacept acts primarily as a soluble IL-1β decoy receptor (or 'cytokine trap'). It also binds IL-1a and IL-1ra. This action reduces signalling via the IL-1R resulting in immunosuppression.

Mechanism Of Action and Pharmacodynamic Effects

Rilonacept acts primarily as a soluble IL-1β decoy receptor (or 'cytokine trap'). It also binds IL-1a and IL-1ra. This action reduces signalling via the IL-1R resulting in immunosuppression.

External links
For extended ADME data see the following: Drugs.com

External links

For extended ADME data see the following:

Drugs.com